Trospium
- Generic Name
- Trospium
- Brand Names
- Trosec
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30NO3
- CAS Number
- 47608-32-2
- Unique Ingredient Identifier
- T4Y8ORK057
- Background
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by Indevus Pharmaceutical Inc. and was granted FDA...
- Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.
- Associated Conditions
- Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 48
- Registration Number
- NCT05880862
- Locations
- 🇺🇸
University of Texas Medical Branch at Galveston, Galveston, Texas, United States
Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Becky Clarkson
- Target Recruit Count
- 220
- Registration Number
- NCT04227184
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 200
- Registration Number
- NCT03709992
- Locations
- 🇪🇬
Ahmed R EL-Nahas, Mansoura, Kuwait, Egypt
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 805
- Registration Number
- NCT03572231
- Locations
- 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷Site KR410009, Incheon, Korea, Republic of
🇰🇷Site KR410005, Kangam, Korea, Republic of
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
- Conditions
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Karuna Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT02831231
- Locations
- 🇺🇸
Medpace, Cincinnati, Ohio, United States
The Effect of Anticholinergics on Cognitive Function in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 59
- Registration Number
- NCT01922115
- Locations
- 🇺🇸
Unc Chapel Hill Urogynecology A2 Clinic, Chapel Hill, North Carolina, United States
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
- Conditions
- Interventions
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 20
- Registration Number
- NCT01178827
Anticholinergic vs. Botox Comparison Study
- Conditions
- Interventions
- First Posted Date
- 2010-07-21
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- NICHD Pelvic Floor Disorders Network
- Target Recruit Count
- 249
- Registration Number
- NCT01166438
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Magee-Women's Hospital, Pittsburgh, Pennsylvania, United States
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
- First Posted Date
- 2010-03-19
- Last Posted Date
- 2013-09-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 322
- Registration Number
- NCT01089751
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.